ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Ajinomoto has agreed to purchase Forge Biologics, a viral vector and plasmid contract development and manufacturing organization, for $620 million. “Forge brings to Ajinomoto an entirely new capability that will vitally enhance our Bio-Pharma Services business,” Yasuyuki Otake, general manager of Ajinomoto’s biopharmaceutical services business, says in a statement. Forge has a 18,580 m2 facility in Columbus, Ohio, called the Hearth. Forge, with approximately 300 employees, will operate as a subsidiary of Ajinomoto.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter